Cargando…

Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies

Detalles Bibliográficos
Autores principales:	Greenberger, Lee M., Saltzman, Larry A., Senefeld, Jonathon W., Johnson, Patrick W., DeGennaro, Louis J., Nichols, Gwen L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2021
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295014/ https://www.ncbi.nlm.nih.gov/pubmed/34331856 http://dx.doi.org/10.1016/j.ccell.2021.07.012

Ejemplares similares

Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies
por: Greenberger, Lee M., et al.
Publicado: (2021)

Sars-Cov-2 Antibody Levels in Blood Cancer Patients after a Third Sars-Cov-2 “Booster” Vaccination - Observational Data from the LLS National Registry
por: Greenberger, Lee M, et al.
Publicado: (2021)

Anti-spike T-cell and Antibody Responses to SARS-CoV-2 mRNA Vaccines in Patients with Hematologic Malignancies
por: Greenberger, Lee M., et al.
Publicado: (2022)

Breakthrough COVID-19 Infections in Patients with Hematologic Malignancies during the Omicron (B.1.1.529) Surge: Data from the Patient-Reported Leukemia & Lymphoma Society National Registry
por: Reddy, Sneha T, et al.
Publicado: (2022)

Danger ahead: COVID-19 infections after vaccination
por: Greenberger, Lee M., et al.
Publicado: (2022)

Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies
por: Malard, Florent, et al.
Publicado: (2021)

Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1
por: Sullivan, David J, et al.
Publicado: (2022)

Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1
por: Sullivan, David J., et al.
Publicado: (2023)

SARS-CoV-2 Vaccination IgG Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Single Center Observation
por: Hoff, Fieke W., et al.
Publicado: (2023)

Therapy in Patients with Hematologic Malignancies, Seroconversion Rates, and SARS-CoV-2 Vaccination
por: Sriwijitalai, Won, et al.
Publicado: (2022)

Convalescent plasma to deliver therapeutic antibodies against COVID-19
por: Senefeld, Jonathon W., et al.
Publicado: (2022)

Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis
por: Gagelmann, Nico, et al.
Publicado: (2021)

Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis
por: Shao, Yacong, et al.
Publicado: (2022)

Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies
por: Tamariz-Amador, Luis-Esteban, et al.
Publicado: (2021)

SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies
por: Haggenburg, Sabine, et al.
Publicado: (2022)

1590P Treatment outcomes and antibody immunity to SARS-CoV-2 in patients with hematological malignancies
por: Zakurdaeva, K., et al.
Publicado: (2021)

HLA Antibody Rates Are Not Increased in a Regional Group of Male COVID-19 Convalescent Plasma Donors
por: Juskewitch, Justin E., et al.
Publicado: (2021)

WITHDRAWN: Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis
por: Wang, Xia, et al.
Publicado: (2022)

Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination
por: Guven, Deniz C, et al.
Publicado: (2022)

SARS-CoV-2 vaccine safety and immunogenicity in patients with hematologic malignancies, transplantation, and cellular therapies
por: Ni, Bin, et al.
Publicado: (2022)

P1593: IMMUNE BIOMARKERS TO PREDICT SARS-COV-2 VACCINE EFFECTIVENESS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
por: Tamariz-Amador, L.-E., et al.
Publicado: (2022)

SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research
por: Guven, Deniz C, et al.
Publicado: (2022)

Sars-CoV2 Antibody Responses in Patients with Hematological Malignancies Following Anti-CD20 Therapy
por: Guerra, Veronica A, et al.
Publicado: (2021)

SARS-CoV-2 vaccination in patients with solid tumors or hematological malignancies: Is the pandemic over for fully vaccinated patients?
por: Zojer, Niklas
Publicado: (2021)

Bispecific Antibodies in the Treatment of Hematologic Malignancies
por: Duell, Johannes, et al.
Publicado: (2019)

Antiphospholipid Antibodies and Lipids in Hematological Malignancies
por: Barreno-Rocha, Sonia Guadalupe, et al.
Publicado: (2022)

Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies
por: Jiménez, Moraima, et al.
Publicado: (2022)

Characterization of post-vaccination SARS-CoV-2 T cell subtypes in patients with different hematologic malignancies and treatments
por: Pfannes, Roald, et al.
Publicado: (2023)

COVID Vaccine Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Better Antibody Response in Patients with Myeloid Malignancies Than B-Cell Malignancies
por: Goksu, Suleyman Y, et al.
Publicado: (2021)

Adherence to Sars-CoV2 vaccination in hematological patients
por: Narinx, Justine, et al.
Publicado: (2022)

Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies
por: Bergamaschi, Cristina, et al.
Publicado: (2022)

P1513: REDUCTION OF THE PROPHYLACTIC EFFECT OF TIXAGEVIMAB-CILGAVIMAB IN THE OMICRON ERA IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AND WITHOUT ANTIBODY RESPONSE FOLLOWING SARS-COV-2 VACCINATION.
por: Callegari, Chiara, et al.
Publicado: (2023)

Beyond SARS-CoV2, the role of viruses in the pathogenesis of hematologic malignancies
por: Wiestner, Adrian
Publicado: (2022)

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
por: van de Donk, Niels W. C. J., et al.
Publicado: (2016)

Evaluation of SARS-CoV-2 Serological Testing in Patients with Multiple Myeloma and Other Hematologic Malignancies on Monoclonal Antibody Therapies
por: Mahimainathan, Lenin, et al.
Publicado: (2020)

Outcomes in Patients with Hematologic Malignancies Infected with Sars-Cov-2: The Northwestern University Experience
por: Galvez, Carlos, et al.
Publicado: (2020)

Descriptive analysis of Cycle Threshold in patients with hematologic malignancies infected with SARS-COV-2
por: Santarelli, Ignacio Martín, et al.
Publicado: (2023)

Serologic Responses Following Sars-Cov-2 Vaccination and Factors Influencing It in Patients with Hematological Malignant and Non-Malignant Diseases - a Prospective Multicentric Study
por: Sertić, Zrinka, et al.
Publicado: (2021)

SARS-CoV-2 Serologic Assays Dependent on Dual-Antigen Binding Demonstrate Diverging Kinetics Relative to Other Antibody Detection Methods
por: Theel, Elitza S., et al.
Publicado: (2021)

Target Therapy in Hematological Malignances: New Monoclonal Antibodies
por: Podhorecka, Monika, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_dk4rtiqumegnkvi5hi135d1drs